

RGT - 7028
Therapeutic DNA Vaccination

Serial No. 09/863,606

Amendments to the Specification

Please cancel Amendments to paragraph bridging pg 22-23 and pg 23-24.

Please substitute the following amendment at pages 23-24, the bridging paragraph:

Of the potential protease inhibitors for use against HIV, compounds such as hydroxyethylamine derivatives, hydroxyethylene derivatives, (hydroxyethyl)urea derivatives, norstatine derivatives, symmetric dihydroxyethylene derivatives, and other dihydroxyethylene derivatives have been suggested, along with protease inhibitors containing the dihydroxyethylene transition state isostere and its derivatives having various novel and high-affinity ligands at the P2 position, including 3-tetrahydrofuran and pyran urethanes, cyclic sulfolanes and tetrahydrofuranylgucines, as well as the P3 position, including pyrazine amides. In addition, constrained "reduced amide"-type inhibitors have been constructed in which three amino acid residues of the polypeptide chain were locked into a g-turn conformation and designated g-turn mimetics. Other alternatives include penicillin-derived compounds and non-peptide cyclic ureas. Suitable protease inhibitors include Indinavir sulfate, (available as CrixivanTM capsules from Merck & Co., Inc, West Point, PA.), saquinavir (Invirase[®] and Fortovase[®] available from Hoffman-LaRoche), ritonavir (Norvir[®] available from Abbott Laboratories) ABT-378 (available from Abbott Laboratories), Nelfinavir (Viracept[®]), and GW141 (available from Glaxo Wellcome/Vertex) Tipranavir available from Pharmacia & Upjohn, PD 178390 available from Parke-Davis, BMS-23632 available from Bristol-Myers Squibb, DMP-450 available from Triangle, and JE 2147 available from Agouron. New protease inhibitors include ABT-378 (Abbott laboratories), L-756423, DMP-450 and AG1776.